Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Monomorphic Epitheliotropic Intestinal T-cell Lymphoma: early-phase trial registry
1 of 2 indexed Monomorphic Epitheliotropic Intestinal T-cell Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Monomorphic Epitheliotropic Intestinal T-cell Lymphoma: 2 US clinical trials tracked, 1 recruiting.
Monomorphic Epitheliotropic Intestinal T-cell Lymphoma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Washington University School of Medicine, running 1 of these trials.
Enrollment posture brief
Registry condition monomorphic-epitheliotropic-intestinal-t-cell-lymphoma
OPEN 1 | RECR 50% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Monomorphic Epitheliotropic Intestinal T-cell Lymphoma lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Monomorphic Epitheliotropic Intestinal T-cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Monomorphic Epitheliotropic Intestinal T-cell Lymphoma is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
National Cancer Institute (NCI)
NCT07388563
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
NCT05377827
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Monomorphic Epitheliotropic Intestinal T-cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Monomorphic Epitheliotropic Intestinal T-cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Monomorphic Epitheliotropic Intestinal T-cell Lymphoma page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Monomorphic Epitheliotropic Intestinal T-cell Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Washington University School of Medicine sponsors the most Monomorphic Epitheliotropic Intestinal T-cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See Washington University School of Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Monomorphic Epitheliotropic Intestinal T-cell Lymphoma condition card totals 2 registered trials; most-linked intervention abatacept; top US site state Missouri. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.